^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Vigil (gemogenovatucel-T)
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Gradalis
Drug class:
GM-CSF agonist, TGF-β1 inhibitor, TGF-β2 inhibitor
Related drugs:
Phase 2
Gradalis, Inc.
Completed
Last update posted :
04/05/2023
Initiation :
05/31/2017
Primary completion :
05/22/2019
Completion :
05/18/2022
PD-L1
|
PD-L1 expression
|
Tecentriq (atezolizumab) • Vigil (gemogenovatucel-T)
Phase 1
Gradalis, Inc.
Completed
Last update posted :
03/15/2022
Initiation :
12/01/2009
Primary completion :
12/06/2018
Completion :
01/01/2019
CSF2
|
Vigil (gemogenovatucel-T)
Phase 2
Mary Crowley Medical Research Center
Completed
Last update posted :
01/27/2021
Initiation :
06/03/2016
Primary completion :
12/30/2019
Completion :
12/02/2020
IFNG
|
PD-L1 expression
|
Imfinzi (durvalumab) • Vigil (gemogenovatucel-T)
Phase 1
Gradalis, Inc.
Completed
Last update posted :
09/27/2017
Initiation :
10/01/2015
Primary completion :
09/01/2017
Completion :
09/01/2017
PD-L1 • BRAF
|
BRAF mutation
|
Keytruda (pembrolizumab) • Vigil (gemogenovatucel-T)
Phase 2
Gradalis, Inc.
Withdrawn
Last update posted :
07/31/2017
Initiation :
03/01/2016
Primary completion :
03/01/2017
Completion :
03/01/2017
EGFR • ALK
|
EGFR mutation • ALK mutation
|
Opdivo (nivolumab) • Vigil (gemogenovatucel-T)
Share
